Trump Pharma Plan Looks Like Reprieve for Many Drugmakers

The Trump administration's proposed plan to impose a 100% tariff on branded and patented drug imports has been met with a tepid response from many investors. The plan includes exemptions for pharmaceutical companies that have manufacturing facilities in the United States, which suggests that the impact on major drugmakers may be limited. The investors' reaction suggests that they believe the proposed tariffs are unlikely to significantly impact the profits of major pharmaceutical companies, as the exemptions for US-based manufacturing facilities would shield many of them from the tariffs. This is seen as a potential reprieve for the industry, as the proposed tariffs could have had a more significant impact on their bottom line. The article suggests that the Trump administration's approach to addressing drug pricing concerns may be perceived as a softer stance towards the pharmaceutical industry, compared to more aggressive measures that could have been taken to address the issue.